For Healthcare Professionals

Pivotal, Randomized, Open-label Study of Optune® (Tumor Treating Fields) Concomitant With RT & TMZ for the Treatment of Newly Diagnosed GBM

clipboard-pencil

About the study

To test the effectiveness and safety of Optune® given concomitantly with radiation therapy (RT) and temozolomide (TMZ) in newly diagnosed GBM patients, compared to radiation therapy and temozolomide alone. In both arms, Optune® and maintenance temozolomide are continued following radiation therapy.
pin location

Study Locations

Enter your ZIP code/Postal code/PIN code to locate study sites near you:

How to Apply


Contact the study center to learn if this study is a good match for you.
Phone iconCall +1 603 206 2337Email iconEmail Study Center

Study’s details


Contition

Glioblastoma Multiforme

Age (in years)

18+

Phase

Not Applicable

Participants needed

950

Est. Completion Date

Aug 31, 2026

Treatment type

Interventional


Sponsor

NovoCure Ltd.

ClinicalTrials.gov identifier

NCT04471844

Study number

TRIDENT EF-32

Understanding Clinical Trials


Get answers to your questions about clinical trials.What is a clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?
Vector

Interested?

Sign up to save your favorites, 
receive newsletters, resources, and alerts 
about clinical trials related to your conditions of interest.